ABSI Share Price Performance
US$2.78
0.08 (2.96%)
65.7% undervalued intrinsic discount
US$8.11
Fair Value
Price US$2.78
AnalystConsensusTarget US$8.11
kg1007 US$9.50
AnalystHighTarget US$10.00
Fair ValueUS$8.11
Share Pricen/a
Absci Corporation Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 62 Fair Values set on narratives written by author
ABSI Community Narratives
AN
Fair Value US$8.11 65.7% undervalued intrinsic discount
Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
KG
Fair Value US$9.5 70.7% undervalued intrinsic discount
Absci will see revenue soar 300% driven by growth min. over the next 3 years
1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
Fair Value US$10 72.2% undervalued intrinsic discount
AI-Driven Antibody Platform Will Unlock Major Aesthetic And Women’s Health Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Absci will see revenue soar 300% driven by growth min. over the next 3 years
AI Driven Drug Discovery/Absci leverages Ai and synthetic biology to revoltionize drug development, reducing costs and timelines, giving them a significant edge in the biotech sector Scalable Platform / Their technology platfrom is highly scalable, improving efficiency with each new project. This makes Absci increasingly competitive as the platform matures.Read more
165
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
Early-Stage Prolactin Antibody Risks Will Eventually Support Long-Term Hair Loss And Endometriosis Potential
Catalysts About Absci Absci uses an AI driven platform to design and develop biologic drug candidates, including its own antibody pipeline and partnered discovery programs. What are the underlying business or industry changes driving this perspective?Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4.54
38.7% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
1.39kx
Price in 2029
US$5.57
AI-Driven Antibody Platform Will Unlock Major Aesthetic And Women’s Health Markets
Catalysts About Absci Absci applies generative AI and biologics engineering to design and develop differentiated antibody therapeutics. What are the underlying business or industry changes driving this perspective?Read more
63
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
72.2% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
93.27x
Price in 2028
US$12.27
Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development
Catalysts About Absci Absci uses an AI driven platform to design and develop novel biologic drugs, advancing its own pipeline and partnered programs. What are the underlying business or industry changes driving this perspective?Read more
77
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$8.11
65.7% undervalued intrinsic discount
Fair Value
Profit Margin
0.16%
Future PE
194.74x
Price in 2028
US$0.1
Trending Discussion
Recently Updated Narratives
KG
Absci will see revenue soar 300% driven by growth min. over the next 3 years
Fair Value: US$9.5 70.7% undervalued intrinsic discount
16 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Early-Stage Prolactin Antibody Risks Will Eventually Support Long-Term Hair Loss And Endometriosis Potential
Fair Value: US$4.54 38.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI-Driven Antibody Platform Will Unlock Major Aesthetic And Women’s Health Markets
Fair Value: US$10 72.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Absci Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.75
- -2,782.79%
- -4,113.68%
- 0.5%
About ABSI
- Founded
- 2011
- Employees
- 140
- CEO
- WebsiteView website
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
